GA-BIOLOG-ID
The Hoxworth Blood Center and Biolog-id signed a partnership contract to manage blood products in Cincinnati metropolitan area
The Biolog-id solution was first implemented in 2018 to focus on the distribution and inventory management of Platelet Concentrates (PCs) between the Blood Center and 4 hospitals located nearby.
In 2019, it is also covering the Phenotyped Red Blood Cell Concentrates (RBCs) managed by the Hoxworth Blood Center’s Immunohematology Reference Laboratory (IRL). The laboratory provides testing and consultation to assist hospitals in solving patients’ red blood cell serological problems.
The implementation of the Biolog-Transfusion® in Hoxworth Blood Center ensures the availability of platelets concentrates and their on-time delivery while reducing the risk of wastage by implementing a safe return of unused products and more particularly to reduce the transportation costs from the Blood Center to the hospitals, control the shelf life of the remote platelets stock sitting in the hospitals, allow the unused products to return and be reassigned in a timely manner before expiration, reduce wastage of products overall, improve accuracy and documentation of inventory and better comply with regulatory requirements.
“As of today, we are satisfied with the BIOLOG-ID solution for platelets as well as their professional and committing team ” says Jose A. Cancelas, Director of Hoxworth Blood Center.
Extension on the overall blood product production and supply is under consideration by Hoxworth Blood Center.
About Hoxworth Blood Center
Hoxworth Blood Center is a
public institution belonging to the University of Cincinnati (OH).
Hoxworth Blood Center collects ~90,000 donations per year and serves
more than 30 hospitals and healthcare centers in the States of Ohio,
Indiana and Kentucky.
About Biolog-id
Biolog-id has developed a patended smart
solution for the management and traceability of sensitive health
products, based on RFID technology: blood products, plasma for
fractionation and chemotherapy. Biolog-id operates in North America,
Europe, Middle East, India and Asia Pacific region and has 90 employees
worldwide. Biolod-id is owned by its founder, managers and the Xerys
Funds
www.biolog-id.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190528005212/en/
Contact:
Amit Mayer
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-VELODYNE-LIDAR29.5.2020 20:33:10 CEST | Press release
Idriverplus Joins the “Automate with Velodyne” Ecosystem
TAKEDA-PHARMACEUTICAL29.5.2020 14:02:17 CEST | Press release
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks
MA-TAKEDA-PHARMACEUTICAL29.5.2020 14:02:06 CEST | Press release
Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS
MA-TAKEDA-PHARMACEUTICAL29.5.2020 14:02:06 CEST | Press release
Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML
DE-INCYTE29.5.2020 14:02:06 CEST | Press release
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings
NY-LETSGETCHECKED29.5.2020 13:59:06 CEST | Press release
LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom